M&A Deal Summary |
|
|---|---|
| Date | 2020-02-10 |
| Target | Valeritas |
| Sector | Medical Products |
| Buyer(s) | Zealand Pharma |
| Deal Type | Special Situations/Distressed |
| Deal Value | 23M USD |
| Advisor(s) | Lincoln International (Financial) DLA Piper PwC Law (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1997 |
| Sector | Life Science |
| Employees | 176 |
| Revenue | 38M DKK (2018) |
Zealand Pharma is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focuses on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and a pre-clinical license collaboration with Alexion Pharmaceuticals. Zealand Pharma was founded in 1997 and is headquartered in Copenhagen, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Medical Products) | 1 of 1 |
| Type (Special Situations/Distressed) | 1 of 1 |
| State (New Jersey) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
